Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Cabaletta Bio in a research report issued on Tuesday, April 1st. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.63) per share for the quarter, up from their prior forecast of ($0.74). HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio's Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.51) EPS, FY2026 earnings at ($2.46) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.30) EPS.
Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.65).
CABA has been the subject of several other research reports. Evercore ISI lowered Cabaletta Bio from an "outperform" rating to an "inline" rating and cut their price objective for the stock from $15.00 to $6.00 in a report on Friday, December 20th. Wells Fargo & Company cut their price target on Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 1st. Guggenheim reiterated a "buy" rating and issued a $23.00 price objective on shares of Cabaletta Bio in a research note on Tuesday, April 1st. UBS Group cut their target price on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Morgan Stanley decreased their price target on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Cabaletta Bio presently has an average rating of "Buy" and an average target price of $21.00.
Read Our Latest Research Report on CABA
Cabaletta Bio Trading Up 12.0 %
NASDAQ:CABA traded up $0.13 during trading hours on Friday, reaching $1.17. The company had a trading volume of 373,925 shares, compared to its average volume of 1,492,371. The firm has a market cap of $59.12 million, a price-to-earnings ratio of -0.54 and a beta of 2.44. The firm's 50 day moving average price is $1.90 and its 200-day moving average price is $2.81. Cabaletta Bio has a 52 week low of $0.99 and a 52 week high of $19.04.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of CABA. Wellington Management Group LLP raised its holdings in Cabaletta Bio by 14.7% during the fourth quarter. Wellington Management Group LLP now owns 180,157 shares of the company's stock valued at $409,000 after acquiring an additional 23,106 shares during the period. Two Sigma Advisers LP boosted its stake in Cabaletta Bio by 195.8% in the 4th quarter. Two Sigma Advisers LP now owns 831,900 shares of the company's stock worth $1,888,000 after purchasing an additional 550,700 shares during the period. Two Sigma Investments LP grew its holdings in Cabaletta Bio by 78.8% during the 4th quarter. Two Sigma Investments LP now owns 751,894 shares of the company's stock valued at $1,707,000 after buying an additional 331,417 shares in the last quarter. Raiffeisen Bank International AG purchased a new stake in Cabaletta Bio during the 4th quarter valued at approximately $493,000. Finally, Point72 Asset Management L.P. raised its position in shares of Cabaletta Bio by 89.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company's stock valued at $2,874,000 after buying an additional 598,607 shares during the last quarter.
About Cabaletta Bio
(
Get Free Report)
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
Featured Stories
Before you consider Cabaletta Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.
While Cabaletta Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
